- GlaxoSmithKline said a HIV treatment developed by ViiV Healthcare, Janssen and a joint venture with Pfizer and Shionogi was granted marketing approval by the European Commission.

The HIV specialist joint venture was granted authorisation for Juluca, which treats HIV type-one infections in adults who are virologically suppressed on a stable anti-retroviral regimen for at least six months.

'The European Commission decision for Juluca is very positive news for people living with HIV across Europe, who will now have the opportunity to maintain their viral suppression with a complete treatment regimen composed of only two drugs within a single-pill,' ViiV chief executive Deborah Waterhouse said.

'Thanks to advances in treatment, many people living with HIV who are on therapy are living longer, with near-normal life expectancies.'

'We listened to their concerns about the potential long-term effects of being on treatment for decades, and have developed a solution aligned with a preference to streamline care by taking fewer antiretrovirals to manage their HIV.' At 1:20pm: [LON:GSK] GlaxoSmithKline PLC share price was +3.2p at 1491.4p

Story provided by